Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21.
daratumumab
functional high risk
multiple myeloma
response adaption
salvage therapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
19
12
2023
accepted:
23
05
2024
medline:
8
6
2024
pubmed:
8
6
2024
entrez:
8
6
2024
Statut:
aheadofprint
Résumé
In Australia, bortezomib-based induction (V-IND) is used in >90% of newly diagnosed transplant-eligible multiple myeloma (MM) patients. Four cycles of V-IND with bortezomib-cyclophosphamide-dexamethasone or bortezomib-lenalidomide-dexamethasone are available via the Pharmaceutical Benefits Scheme prior to autologous stem cell transplantation (ASCT). Patients who demonstrate suboptimal response or who are refractory to V-IND demonstrate inferior survival, representing a subgroup of MM where an unmet need persists. We evaluated an early, response-adapted approach in these patients by switching to an intensive sequential therapeutic strategy incorporating daratumumab-lenalidomide-dexamethasone-based (DRd) salvage, high-dose melphalan ASCT followed by DRd consolidation and R maintenance. The overall response rate following four cycles of DRd salvage was 72% (95% credible interval: 57.9-82.4); prespecified, dual, Bayesian proof-of-concept criteria were met. Euro-flow minimal residual disease (MRD) negativity was 46% in the intention-to-treat population and 79% in the evaluable population following 12 cycles of DRd consolidation. At the 24-month follow-up, median progression-free survival and overall survival were not reached. DRd salvage was well tolerated with grade 3 and 4 events reported in 24% and 8% respectively. Response-adapted DRd combined with ASCT achieves high rates of MRD negativity and durable disease control in this functional high-risk group.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Celgene
Organisme : Cilag
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
Cohen YC, Joffe E, Benyamini N, Dimopoulos MA, Terpos E, Trestman S, et al. Primary failure of bortezomib in newly diagnosed multiple myeloma—understanding the magnitude, predictors, and significance. Leuk Lymphoma. 2016;57(6):1382–1388.
Schaar CG, Kluin‐Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004;125(2):162–166.
Shimizu K, Kamiya O, Hirabayashi N, Ichikawa A, Kawashima K, Kobayashi M, et al. Posttreatment M‐protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group. Jpn J Cancer Res. 1999;90(3):355–360.
Shimizu K, Nagura E, Hirabayashi N, Wakita A, Takeyama H, Sao H, et al. Posttreatment nadir M‐protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M‐protein in patients with IgG myeloma. Int J Hematol. 2001;74(2):205–208.
Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer. 2011;117(16):3758–3762.
Turner R, Quach H, Horvath N, Kerridge I, Lee E, Morris E, et al. Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—the Australasian Leukemia and Lymphoma Group (ALLG) MM17 trial. Br J Haematol. 2023;202:530–538.
Spencer A, Mollee P, Blacklock HA, Harrison S, Quach H, Ho PJ, et al. Real‐world outcome for newly diagnosed patients with functional high‐risk myeloma—a Myeloma and Related Diseases Registry analysis. Blood. 2019;134(Suppl 1):269.
van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T‐cell expansion, and skews T‐cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020;7(6):e447–e455.
Palumbo A, Chanan‐Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
Dimopoulos MA, Oriol A, Nahi H, San‐Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‐cell transplant (SWOG S0777): a randomised, open‐label, phase 3 trial. Lancet. 2017;389(10068):519–527.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant‐eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945.
Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305.
Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c‐Myc and IRF4. Blood Cancer J. 2015;5(10):e354.
Cippitelli M, Stabile H, Kosta A, Petillo S, Gismondi A, Santoni A, et al. Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them. Int J Mol Sci. 2021;22(3):1103.
Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, et al. IMiDs prime myeloma cells for daratumumab‐mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132(20):2166–2178.
Neuenschwander B, Rouyrre N, Hollaender N, Zuber E, Branson M. A proof of concept phase II non‐inferiority criterion. Stat Med. 2011;30(13):1618–1627.
Roychoudhury S, Scheuer N, Neuenschwander B. Beyond p‐values: a phase II dual‐criterion design with statistical significance and clinical relevance. Clin Trials. 2018;15(5):452–461.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691–4695.
Dimopoulos MA, San‐Miguel J, Belch A, White D, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096.
Andrew Spencer PM, Mateos M‐V, Goldschmidt H, Suzuki K, Levin M‐D, Sonneveld P, et al. Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D‐Vd) or lenalidomide plus dexamethasone (D‐Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy. J Clin Oncol. 2022;40(16):8052.
Kumar S, Williamson M, Ogbu U, Surinach A, Arndorfer S, Hong WJ. Front‐line treatment patterns in multiple myeloma: an analysis of U.S.‐based electronic health records from 2011 to 2019. Cancer Med. 2021;10(17):5866–5877.
Weisel K, Wadlund AO, Gungor G, Dergarabetian E, Pacheco C, Masurkar N, et al. Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy. Eur J Haematol. 2022;109(4):388–397.
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih‐Khan E, et al. Real‐world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023;13(1):137.
Tang W, Yang J, Li Y, Zhang L, Li H, Wang J, et al. Treatment attrition rates and relevant risk factors in multiple myeloma: a real‐world study in China. Front Pharmacol. 2023;14:979111.
Sandecká V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, et al. Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. Eur J Haematol. 2021;107(4):466–474.
Popková T, Pour L, Spicka I, Radocha J, Jungova A, Minarik J, et al. P1294: real‐world outcomes of 2149 newly diagnosed transplant‐eligible multiple myeloma patients. HemaSphere. 2023;7(S3):e0151603.
Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, et al. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma—analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma. 2019;66(3):499–505.
Tang A, Kim K, Chen F, McQuilten ZK, Mollee P, Rajagopal R, et al. A prospective, multinational study of clinical and biological factors associated with short overall survival in multiple myeloma. Blood. 2023;142(Suppl 1):4731.
Schütz NP, Ochoa P, Duarte P, Remaggi G, Yantorno S, Corzo A, et al. Real world outcomes with bortezomib thalidomide dexamethasone and cyclophosphamide bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A retrospective cohort study from Grupo Argentino de Mieloma Múltiple. Hematol Oncol. 2020;38(3):363–371.
Drummond PLM, Santos R, Reis AMM, Malta JS, Silveira LP, Costa I, et al. Real‐world effectiveness and safety of multiple myeloma treatments based on thalidomide and bortezomib: a retrospective cohort study from 2009 to 2020 in a Brazilian metropolis. Cancer Epidemiol. 2023;85:102377.
Nasr F, Ghoche AA, Diab S, Nasr L, Ammanouil E, Riachy C, et al. Lebanese real‐world experience in treating multiple myeloma: a multicenter retrospective study. Leuk Res Rep. 2021;15:100252.
Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real‐world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato‐oncologic malignancies in Colombia, observational study. Clin Lymphoma Myeloma Leuk. 2022;22(6):e405–e413.
Weisel K, Geils GF, Karlin L, Mollee P, Chung T‐H, Min C‐K, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of the phase 3 candor study in patients with early or late relapse. Blood. 2020;136(Suppl 1):37–38.
Facon T, Moreau P, Baker R, Pour L, Min C‐K, Leleu X, et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: Ikema subgroup analysis. Blood. 2022;140(Suppl 1):1820–1822.
Spencer A, Moreau P, Mateos MV, Goldschmidt H, Suzuki K, Levin MD, et al. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024;8(2):388–398.
Thurlapati A, Roubal K, Davis JA, Shah SZ, Smith D, McGann M, et al. Stem cell mobilization for multiple myeloma patients receiving daratumumab‐based induction therapy: a real‐ world experience. Transplant Cell Ther. 2023;29(5):340.e1–340.e4.
Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, et al. Stem cell mobilization yields with daratumumab‐ and lenalidomide‐containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2023;29(3):174.e1–174.e10.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–313.
Soekojo CY, Chung T‐H, Furqan MS, Chng W‐J. Identifying the genomic profile of functional high‐risk multiple myeloma patients. Blood. 2020;136(Suppl 1):51–52.